The article reviews the Dexcom Stelo, an over-the-counter AI-enabled continuous glucose monitor, comparing its accuracy and usability to traditional finger-stick monitors over two weeks. The device provides real-time glucose data, lifestyle insights, and stress-related alerts, with potential for future AI enhancements. While initial results show promising accuracy and user benefits, the device's features are still developing, and it costs $99 per month, making it suitable mainly for those managing prediabetes or metabolic health.
The FDA has approved the first over-the-counter continuous glucose monitor, the Dexcom Stelo Glucose Biosensor System, designed for individuals 18 years and older who do not use insulin. This integrated CGM allows users to monitor and analyze glucose levels using a wearable sensor and a smartphone app, providing valuable information about their health without the involvement of a healthcare provider. However, it is not intended for individuals with problematic hypoglycemia. This approval aligns with the FDA's goal of advancing health equity by expanding access to valuable health information for all patients.
